CMV Reactivations During and after Letermovir Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation: a Single-Center Experience.
Main Article Content
Keywords
Downloads
Download data is not yet available.
Abstract 31
PDF Downloads 13
Html Downloads 8
References
1. Schmidt-Hieber, M. et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT. Ann Hematol 98, 1755–1763 (2019). https://doi.org/10.1007/s00277-019-03669-z
2. Ganepola, S. et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 39, 293–299 (2007). https://doi.org/10.1038/sj.bmt.1705585
3. Stern, L. et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol 10, (2019). https://doi.org/10.3389/fmicb.2019.01186
4. Ljungman, P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 42, (2008). https://doi.org/10.1038/bmt.2008.120
5. Ljungman, P., Hakki, M. & Boeckh, M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 24, 319–337 (2010). https://doi.org/10.1016/j.idc.2010.01.008
6. Marty, F. M. et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. New England Journal of Medicine 377, 2433–2444 (2017). https://doi.org/10.1056/NEJMoa1706640
7. Herrera, F. et al. Letermovir Primary Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: Real-Life Data from a University Hospital in Argentina. Mediterr J Hematol Infect Dis 16, (2024). https://doi.org/10.4084/MJHID.2024.039
8. Gabanti, E. et al. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. Transplant Cell Ther 28, 211.e1-211.e9 (2022). https://doi.org/10.1016/j.jtct.2022.01.008
9. Liu, L. W. et al. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. Transplant Cell Ther 28, 510.e1-510.e9 (2022). https://doi.org/10.1016/j.jtct.2022.05.020
10. Girmenia, C. et al. The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome after Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letermovir Prophylaxis. Open Forum Infect Dis 12, (2025). https://doi.org/10.1093/ofid/ofaf233
11. Russo, D. et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 11, e127–e135 (2024). https://doi.org/10.1016/S2352-3026(23)00344-7
12. Spyridonidis, A. et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant 55, 1114–1125 (2020). https://doi.org/10.1038/s41409-020-0803-y
2. Ganepola, S. et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant 39, 293–299 (2007). https://doi.org/10.1038/sj.bmt.1705585
3. Stern, L. et al. Human cytomegalovirus latency and reactivation in allogeneic hematopoietic stem cell transplant recipients. Front Microbiol 10, (2019). https://doi.org/10.3389/fmicb.2019.01186
4. Ljungman, P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 42, (2008). https://doi.org/10.1038/bmt.2008.120
5. Ljungman, P., Hakki, M. & Boeckh, M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 24, 319–337 (2010). https://doi.org/10.1016/j.idc.2010.01.008
6. Marty, F. M. et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. New England Journal of Medicine 377, 2433–2444 (2017). https://doi.org/10.1056/NEJMoa1706640
7. Herrera, F. et al. Letermovir Primary Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: Real-Life Data from a University Hospital in Argentina. Mediterr J Hematol Infect Dis 16, (2024). https://doi.org/10.4084/MJHID.2024.039
8. Gabanti, E. et al. Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. Transplant Cell Ther 28, 211.e1-211.e9 (2022). https://doi.org/10.1016/j.jtct.2022.01.008
9. Liu, L. W. et al. Letermovir Discontinuation at Day 100 After Allogeneic Stem Cell Transplant Is Associated With Increased CMV-Related Mortality. Transplant Cell Ther 28, 510.e1-510.e9 (2022). https://doi.org/10.1016/j.jtct.2022.05.020
10. Girmenia, C. et al. The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome after Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letermovir Prophylaxis. Open Forum Infect Dis 12, (2025). https://doi.org/10.1093/ofid/ofaf233
11. Russo, D. et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol 11, e127–e135 (2024). https://doi.org/10.1016/S2352-3026(23)00344-7
12. Spyridonidis, A. et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant 55, 1114–1125 (2020). https://doi.org/10.1038/s41409-020-0803-y
Article Sidebar
Published
Oct 31, 2025
Article Details
How to Cite
Olivari, E. (2025) “CMV Reactivations During and after Letermovir Prophylaxis In Allogeneic Hematopoietic Stem Cell Transplantation: a Single-Center Experience”., Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025079. doi: 10.4084/MJHID.2025.079.
Section
Letters to the Editor
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers. Authors will grant copyright of their articles to the Institute of Hematology, Catholic University, Rome . No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.